Acute Kidney Injury: Diagnosis and Management

Acute kidney injury (AKI) represents a rapid decline in renal function occurring over hours to days, characterized by an abrupt decrease in glomerular filtration rate (GFR). This clinical syndrome affects 10-15% of hospitalized patients and carries significant morbidity and mortality.

KDIGO Criteria for AKI Diagnosis

The Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI as any of the following:

AKI Staging

Mnemonic: "AKI RISE"

• Rapid onset (hours to days)
• Increased creatinine
• Staging system (1-3)
• Evaluate cause (pre/intrinsic/post)

Early recognition is crucial as timely intervention can prevent progression to chronic kidney disease or end-stage renal disease. The pathophysiology involves disruption of normal homeostatic mechanisms including fluid balance, electrolyte regulation, and waste elimination.

AKI is traditionally classified into three categories based on the anatomical location and mechanism of injury. This classification system guides diagnostic workup and therapeutic interventions.

Pre-renal AKI (70-80% of cases)

Pre-renal AKI results from decreased renal perfusion with structurally normal kidneys. The kidney responds appropriately to hypoperfusion by conserving sodium and water.

Common Causes:

• Hypovolemia: Dehydration, hemorrhage, burns, diarrhea
• Decreased cardiac output: Heart failure, cardiogenic shock, cardiac arrest
• Systemic vasodilation: Sepsis, anaphylaxis, medications (ACE inhibitors, ARBs)
• Renal vasoconstriction: NSAIDs, hepatorenal syndrome, contrast agents

Intrinsic AKI (10-20% of cases)

Intrinsic AKI involves direct damage to renal parenchyma, including glomeruli, tubules, interstitium, or vessels.

Subtypes and Causes:

Post-renal AKI (5-10% of cases)

Post-renal AKI occurs due to obstruction of urine flow anywhere from the renal pelvis to the urethra.

Causes by Location:

• Upper tract: Nephrolithiasis, blood clots, tumors, retroperitoneal fibrosis
• Lower tract: BPH, prostate cancer, bladder cancer, neurogenic bladder

Key Point: Bilateral obstruction or unilateral obstruction in a solitary kidney is required for AKI development.

This classification system provides a systematic approach to AKI evaluation, with each category having distinct diagnostic features and management strategies.

The diagnostic evaluation of AKI requires a systematic approach combining history, physical examination, and targeted laboratory investigations. Early and accurate diagnosis is essential for appropriate management.

Clinical Assessment

History Focus:

• Medication review (nephrotoxins, diuretics)
• Recent procedures (contrast exposure, surgery)
• Volume status (fluid losses, intake)
• Symptoms of obstruction (decreased urine stream, nocturia)

Physical Examination:

• Volume status assessment (JVP, skin turgor, mucous membranes)
• Blood pressure and orthostatic changes
• Edema, rashes, or signs of systemic disease
• Bladder distension or flank tenderness

Essential Laboratory Tests

Urinalysis Components

Microscopy Findings by AKI Type:

Additional Investigations

Imaging Studies:

• Renal ultrasound: First-line imaging to assess kidney size, hydronephrosis
• CT scan: Detailed evaluation for obstruction, stones, masses
• Doppler studies: Assess renal blood flow if vascular cause suspected

The combination of clinical assessment and targeted investigations allows for rapid categorization of AKI type and guides subsequent management decisions.

Fractional excretion of sodium (FENa) is a critical diagnostic tool that helps differentiate pre-renal AKI from acute tubular necrosis (ATN). This calculation assesses the kidney's ability to conserve sodium, reflecting tubular function integrity.

FENa Calculation and Interpretation

Formula: FENa = (Urine Na⁺ × Serum Creatinine) / (Serum Na⁺ × Urine Creatinine) × 100%

Alternative calculation using spot urine: FENa = (UNa × SCr) / (SNa × UCr) × 100

Diagnostic Thresholds

Clinical Limitations of FENa

Conditions with falsely low FENa in ATN:

• Contrast-induced nephropathy (early phase)
• Pigment nephropathy (rhabdomyolysis, hemolysis)
• Acute glomerulonephritis
• Sepsis-related AKI

Conditions with falsely elevated FENa in pre-renal states:

• Diuretic use (within 24-48 hours)
• Chronic kidney disease
• Sodium-wasting nephropathy
• Adrenal insufficiency

Alternative Diagnostic Indices

Fractional Excretion of Urea (FEUrea):

• Formula: (UUrea × SCr) / (SUrea × UCr) × 100%
• Advantage: Not affected by diuretics
• Threshold: <35% suggests pre-renal, >50% suggests ATN

Renal Failure Index (RFI):

• Formula: UNa ÷ (UCr ÷ SCr)
• Threshold: <1 suggests pre-renal, >2 suggests ATN

Practical Application Algorithm

AKI Patient with Oliguria ↓ Check recent diuretic use ↓ No diuretics → Calculate FENa ↓ FENa <1% → Pre-renal likely FENa >2% → ATN likely FENa 1-2% → Calculate FEUrea or assess other factors

Mnemonic: "FENA Less than One, Pre-renal's the One"

These diagnostic indices should always be interpreted in conjunction with clinical context, urinalysis findings, and response to therapeutic interventions.

Urinalysis provides crucial diagnostic information in AKI evaluation, with specific patterns corresponding to different etiologies. Systematic interpretation of urinalysis findings can rapidly narrow the differential diagnosis and guide management.

Systematic Urinalysis Interpretation

Physical Examination of Urine

Chemical Analysis

Proteinuria Patterns:

• Minimal (<1+): Pre-renal AKI, early ATN
• Moderate (1-2+): ATN, acute interstitial nephritis
• Heavy (3-4+): Glomerular disease, severe ATN

Hematuria Significance:

• Microscopic: Common in various AKI types
• Gross hematuria: Suggests glomerular disease, stones, or malignancy

Microscopic Examination Patterns

Cast Analysis - The Key to Diagnosis

Cellular Elements

Red Blood Cells:

• Dysmorphic RBCs (>20%): Glomerular bleeding
• Eumorphic RBCs: Lower urinary tract bleeding

White Blood Cells:

• Neutrophils: Bacterial infection, ATN
• Eosinophils: Drug-induced AIN, atheroembolic disease
• Lymphocytes: Viral infections, chronic inflammation

Epithelial Cells:

• Tubular epithelial cells: ATN, acute rejection
• Transitional cells: Normal shedding, instrumentation

Diagnostic Patterns by AKI Type

Pre-renal AKI Urinalysis Pattern

• Specific gravity >1.020
• Minimal proteinuria
• Few hyaline casts
• Minimal cellular elements
• FENa <1%

ATN Urinalysis Pattern

• Specific gravity 1.010-1.012 (isosthenuric)
• Mild proteinuria (1-2+)
• Muddy brown granular casts
• Tubular epithelial cells
• FENa >2%

Glomerular Disease Pattern

• Variable specific gravity
• Heavy proteinuria (3-4+)
• RBC casts and dysmorphic RBCs
• Possible WBC casts

Clinical Pearl: The presence of muddy brown granular casts is pathognomonic for ATN and distinguishes it from pre-renal azotemia.

Management of AKI requires a systematic approach addressing the underlying cause while preventing further kidney injury and managing complications. Early intervention can significantly improve outcomes and prevent progression to chronic kidney disease.

Initial Management Algorithm

AKI Diagnosis Confirmed ↓ Immediate Assessment: • Hemodynamic stability • Volume status • Electrolyte abnormalities • Drug review ↓ Categorize AKI Type: Pre-renal → Volume management Intrinsic → Supportive care + specific therapy Post-renal → Relieve obstruction ↓ Ongoing monitoring: • Daily weights, I/O • Electrolytes, creatinine • Urine output

Pre-renal AKI Management

Volume Assessment and Resuscitation:

Medication Management:

• Discontinue: NSAIDs, ACE inhibitors/ARBs (temporarily), diuretics
• Avoid: Nephrotoxic agents (aminoglycosides, contrast)
• Adjust dosing: Renally cleared medications

Intrinsic AKI Management

Acute Tubular Necrosis (ATN)

Supportive Care Principles:

• Maintain euvolemia (avoid both dehydration and fluid overload)
• Optimize renal perfusion (MAP >65 mmHg)
• Avoid nephrotoxins
• Nutritional support (protein 1.2-1.5 g/kg/day)

Acute Interstitial Nephritis

• Primary intervention: Discontinue offending agent
• Corticosteroids: Prednisolone 1 mg/kg/day if severe (controversial)
• Duration: Taper over 4-6 weeks if used

Glomerulonephritis

• Immunosuppression: Based on specific diagnosis
• Plasmapheresis: For severe RPGN or Goodpasture syndrome
• Blood pressure control: ACE inhibitors when hemodynamically stable

Post-renal AKI Management

Obstruction Relief Strategies:

Complications Management

Electrolyte Abnormalities

Hyperkalemia (K⁺ >5.5 mmol/L):

• Immediate: Calcium gluconate 10% 10 mL IV (if ECG changes)
• Short-term: Insulin + glucose, salbutamol nebulizer, sodium bicarbonate
• Long-term: Kayexalate, dietary restriction, dialysis

Metabolic Acidosis:

• Mild (HCO₃⁻ >15 mmol/L): Supportive care
• Severe (HCO₃⁻ <15 mmol/L): Sodium bicarbonate, dialysis consideration

Fluid Overload

• Diuretics: Furosemide 40-80 mg IV (if responsive)
• Ultrafiltration: If diuretic-resistant
• Dialysis: If severe with pulmonary edema

Renal Replacement Therapy Indications

"AEIOU" Mnemonic:

• Acidosis (severe, pH <7.1)
• Electrolyte abnormalities (hyperkalemia >6.5 mmol/L)
• Intoxications (methanol, ethylene glycol)
• Overload (fluid, refractory pulmonary edema)
• Uremia (pericarditis, encephalopathy, bleeding)

Modality selection (hemodialysis vs. CRRT) depends on hemodynamic stability and clinical context.

Understanding AKI prognosis and implementing prevention strategies are crucial for improving patient outcomes. Early recognition and intervention can significantly reduce morbidity, mortality, and progression to chronic kidney disease.

Prognostic Factors and Outcomes

Short-term Prognosis

Factors Associated with Poor Prognosis:

• Advanced age (>65 years)
• Comorbidities (diabetes, heart failure, cirrhosis)
• Severity of illness (sepsis, multi-organ failure)
• Oliguria duration >3 days
• Requirement for renal replacement therapy
• Baseline chronic kidney disease

Long-term Outcomes

Risk of Chronic Kidney Disease:

• Complete recovery: 60-70% of patients
• Partial recovery: 20-25% (increased CKD risk)
• No recovery: 10-15% (ESRD or death)

Cardiovascular Risk:

• 2-3 fold increased risk of cardiovascular events
• Higher mortality even after complete renal recovery
• Accelerated progression of pre-existing CKD

AKI Prevention Strategies

High-Risk Patient Identification

Risk Assessment Tools:

High Risk: Score ≥5 requires intensive monitoring

Nephrotoxin Prevention

Contrast-Induced Nephropathy Prevention:

Patient receiving contrast ↓ Assess baseline eGFR ↓ eGFR <60 mL/min/1.73m²? ↓ Yes → High risk protocol: • IV hydration (0.9% saline 1 mL/kg/h × 12h pre/post) • Minimize contrast volume • Avoid NSAIDs • Consider N-acetylcysteine 600mg PO BID ↓ Monitor creatinine 48-72h post-procedure

Drug-Induced AKI Prevention:

• Aminoglycosides: Monitor levels, limit duration, avoid dehydration
• NSAIDs: Use lowest effective dose, avoid in high-risk patients
• Vancomycin: Monitor trough levels, avoid nephrotoxic combinations

Perioperative AKI Prevention

Preoperative Optimization:

• Optimize volume status and hemodynamics
• Discontinue nephrotoxic medications 48h before surgery
• Consider ACE inhibitor/ARB hold in major surgery

Intraoperative Management:

• Maintain adequate perfusion pressure
• Avoid nephrotoxic anesthetics
• Monitor urine output and fluid balance

Postoperative Monitoring:

• Daily creatinine for 48-72 hours
• Maintain euvolemia
• Early mobilization and nutrition

Hospital-Wide AKI Prevention Programs

"Bundle" Approach Components:

• Electronic alerts for high-risk patients
• Automatic nephrotoxin alerts
• Standardized hydration protocols
• Regular medication reconciliation
• Staff education programs

Quality Improvement Metrics:

• AKI incidence rates
• Time to AKI recognition
• Nephrotoxin exposure rates
• Preventable AKI cases

Recovery and Follow-up

Post-AKI Care Algorithm:

AKI Resolution (creatinine returning to baseline) ↓ Assess recovery completeness: • Complete: Creatinine <120% baseline • Partial: Creatinine 120-200% baseline • No recovery: Creatinine >200% baseline ↓ Follow-up plan: • Nephrology referral if partial/no recovery • CKD screening at 3 months • Cardiovascular risk assessment • Medication review and adjustment

Long-term Management:

• Annual eGFR and proteinuria assessment
• Blood pressure optimization (<130/80 mmHg)
• Diabetes control (HbA1c <7%)
• Cardiovascular risk factor modification
• Patient education on AKI risk factors